EXACT Sciences (NASDAQ:EXAS) Raised to Buy at ValuEngine

EXACT Sciences (NASDAQ:EXAS) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Saturday, ValuEngine reports.

EXAS has been the topic of several other reports. Zacks Investment Research cut shares of EXACT Sciences from a “buy” rating to a “hold” rating and set a $92.00 price target on the stock. in a report on Tuesday, January 21st. Robert W. Baird restated a “buy” rating on shares of EXACT Sciences in a report on Wednesday. Canaccord Genuity restated a “buy” rating and set a $120.00 price target on shares of EXACT Sciences in a report on Wednesday. Bank of America reaffirmed a “buy” rating and issued a $135.00 price objective on shares of EXACT Sciences in a research note on Thursday, October 31st. Finally, Stifel Nicolaus assumed coverage on shares of EXACT Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $110.00 price objective for the company. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $121.00.

EXACT Sciences stock opened at $98.18 on Friday. The company’s fifty day simple moving average is $94.13 and its 200-day simple moving average is $97.43. The company has a quick ratio of 2.63, a current ratio of 2.75 and a debt-to-equity ratio of 0.67. EXACT Sciences has a 12 month low of $75.35 and a 12 month high of $123.99. The stock has a market cap of $12.58 billion, a P/E ratio of -57.41 and a beta of 1.36.

EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.54 EPS for the quarter, beating the consensus estimate of ($0.37) by $0.91. EXACT Sciences had a negative net margin of 29.83% and a negative return on equity of 29.06%. The business had revenue of $295.58 million for the quarter, compared to analysts’ expectations of $294.39 million. On average, equities research analysts expect that EXACT Sciences will post -1.64 earnings per share for the current fiscal year.

In related news, insider G Bradley Cole sold 28,016 shares of EXACT Sciences stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $80.38, for a total value of $2,251,926.08. Following the completion of the sale, the insider now owns 30,987 shares of the company’s stock, valued at approximately $2,490,735.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.20% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in EXAS. Artisan Partners Limited Partnership lifted its position in EXACT Sciences by 20.7% during the 4th quarter. Artisan Partners Limited Partnership now owns 2,191,714 shares of the medical research company’s stock worth $202,690,000 after acquiring an additional 375,796 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in EXACT Sciences during the 4th quarter worth $33,163,000. Factory Mutual Insurance Co. acquired a new position in EXACT Sciences during the 4th quarter worth $27,181,000. D1 Capital Partners L.P. acquired a new position in EXACT Sciences during the 4th quarter worth $25,432,000. Finally, Spyglass Capital Management LLC lifted its position in EXACT Sciences by 205.5% during the 4th quarter. Spyglass Capital Management LLC now owns 387,117 shares of the medical research company’s stock worth $35,801,000 after acquiring an additional 260,397 shares during the last quarter. 87.01% of the stock is owned by hedge funds and other institutional investors.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Recommended Story: Book Value Per Share in Stock Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.